Being awarded WHO-GMP, PICs and EU certifications, this stands as a testament to its unwavering commitment to maintaining the highest quality standards in pharmaceutical manufacturing.
View Plant Details
Milestones
• First Manufacturing Setup at Amritsar
with
Generic Liquid Orals & Injectables Facility (1983)
• Target Markets of Africa & ASEAN Countries (2000)
• New manufacturing with OSD and Injectable capabilities for general
therapiesand beta-lactam added (2007)
• Started Marketing Office in Africa • Setup of new manufacturing in HP (2010)
• WHO approval for Amritsar facility
• New facility setup for Oncology products
• Started Exporting to Gulf Countries (2012)
• Libya, Ivory Coast, Nigeria approval for
Amritsar facility (2015)
• Listed on BSE SME Exchange (2016)
• Upgraded Generics Block (2017)
• PICs/GMP from Iran, Iraq & Tanzania
• Upgraded Oncology facility Unit 3 in HP (2018)
• New Cephalosporin facility in HP (2019)
• 11 molecules registered in EMs
• WHO approval for Cephalosporin Unit
• Enhanced injectables capabilities at Amritsar (2021)
• Established Beta-lactam Unit
• Developed 10+ complex products including
microspheres, Liposomes, Ophthalmic susp.
• PIC/s GMP from Brazil for 3 Units
• Migrated to Main Board of BSE Ltd (2022)
• EU-GMP for Cephalosporin & Oncology Units
• Established Biologics Unit (2023)
Milestones
Got registered with
the Bombay Stock Exchange in 2016
Continuous upgradation of our state of the art manufacturing units by installing the latest equipment for the production of best quality products.
Started production of Cytotoxic drugs, following EU standards at our new unit at Jassur, Himachal Pradesh.
Attained PIC/S GMP accreditation for FDA, Iran
Developed our own integrated software – “Friends” – for prompt updates for customer service and information
World-class QA, QC, Micro Lab, R&D to ensure best in class quality
11 Molecules registered in emerging markets
WHO approved for cephalosporin unit
Enhanced injectables capabilities at Amritsar facility
Developed over 10 comples products including microspheres, Liposomes, Ophthalmic susp, etc
MANUFACTURING SETUP
| Locations | |
|||||
|---|---|---|---|---|---|---|
| Unit Names | Unit -1 Block A & Block W1 |
Unit-2 | Unit-5 *Proposed |
Unit-6 | Unit-3 | Unit-4 |
| Establishment Year | 2017 (Upgraded) 2007 (First Built) |
FY22 | FY25/FY26 Estimated |
FY24 | FY18 | FY19 |
| Therapy | Critical Care, Anaesthesia, Cardiac, Pain Management and systemic anti infectives | Beta-lactam, anti infectives | Sex Hormones and synthetic hormones | Biologics – mammalian cell line ( Chinese hamster ovary derivative) | Cytotoxic (Onco) & Allied products | Cephalosporins, Anti Infectives |
| Dosage Forms | Tablets, Capsules, Oral liquid, Sachets, Dry powder for suspension, Lyophilized injections, Vials & ampoules Eye / Ear / Nasal drops & cream / ointment / lotion / Gel / Suppositories | Tablets/Capsules, Dry powder for suspension, Injections | Tablets, Lyophilized injections, implants, Vials and ampoules, Cream / ointment / lotion / Gel / Suppositories | Pre filled syringes (PFS) and Vials Lyophilized injections | Tablets/Capsules, Lyophilized injections | Tablets/Capsules, Dry powder for suspension, Lyophilized injections |
| Key Regulatory Approvals | Already Approved From PIC/S, ANVISA (Brazil) | Medium Term Plan to apply for ANVISA , EU GMP and USFDA | Future | Long Term Plans to apply for ANVISA & EU GMP | PIC/S, ANVISA (Brazil) EU GMP | PIC/S, ANVISA (Brazil) EU GMP |
| *Unit 5 is being planned for Hormones. | ||||||
